Your browser is no longer supported. Please, upgrade your browser.
NTLA Intellia Therapeutics, Inc. daily Stock Chart
Intellia Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.25 Insider Own0.90% Shs Outstand50.49M Perf Week6.77%
Market Cap1.32B Forward P/E- EPS next Y-2.91 Insider Trans-4.09% Shs Float46.30M Perf Month15.53%
Income-109.40M PEG- EPS next Q-0.69 Inst Own71.60% Short Float21.66% Perf Quarter82.45%
Sales45.60M P/S28.89 EPS this Y-6.30% Inst Trans3.04% Short Ratio10.05 Perf Half Y55.42%
Book/sh4.91 P/B4.85 EPS next Y-11.50% ROA-32.50% Target Price28.65 Perf Year44.22%
Cash/sh4.52 P/C5.26 EPS next 5Y30.00% ROE-40.90% 52W Range9.18 - 25.56 Perf YTD62.30%
Dividend- P/FCF- EPS past 5Y-50.60% ROI- 52W High-6.85% Beta1.73
Dividend %- Quick Ratio7.60 Sales past 5Y- Gross Margin- 52W Low159.37% ATR1.58
Employees270 Current Ratio7.60 Sales Q/Q24.00% Oper. Margin- RSI (14)63.16 Volatility7.03% 7.11%
OptionableYes Debt/Eq0.00 EPS Q/Q-29.90% Profit Margin- Rel Volume0.78 Prev Close24.57
ShortableYes LT Debt/Eq0.00 EarningsMay 07 BMO Payout- Avg Volume997.90K Price23.81
Recom2.10 SMA209.96% SMA5023.96% SMA20058.55% Volume781,443 Change-3.09%
Feb-28-20Upgrade Oppenheimer Perform → Outperform
Feb-14-20Downgrade Wedbush Outperform → Neutral $16
Nov-01-19Upgrade Raymond James Mkt Perform → Outperform
Jul-09-19Initiated Robert W. Baird Outperform $23
Jun-10-19Initiated ROTH Capital Neutral $16
May-03-19Upgrade Wedbush Neutral → Outperform $20 → $21
Apr-12-19Initiated Evercore ISI Outperform
Nov-02-18Downgrade Wedbush Outperform → Neutral $36 → $20
Oct-29-18Initiated Credit Suisse Neutral $24
Sep-21-18Initiated Raymond James Mkt Perform
May-15-18Upgrade Chardan Capital Markets Neutral → Buy $20 → $57.50
Mar-08-18Initiated JMP Securities Mkt Outperform $76
Nov-01-17Reiterated Jefferies Buy $36 → $42
Jun-22-17Resumed Jefferies Buy $36
Mar-28-17Initiated Chardan Capital Markets Buy $19
Aug-05-16Upgrade Jefferies Hold → Buy
May-31-16Initiated Wedbush Outperform $38
May-31-16Initiated Leerink Partners Mkt Perform
May-31-16Initiated Jefferies Hold $33
May-31-16Initiated Credit Suisse Outperform $39
Jul-05-20 10:52PM  
Jul-02-20 11:32AM  
Jun-10-20 11:48PM  
Jun-05-20 04:01PM  
Jun-03-20 09:56AM  
Jun-02-20 09:00PM  
Jun-01-20 04:00PM  
May-22-20 07:39AM  
May-18-20 07:12PM  
May-12-20 06:00AM  
May-11-20 07:43AM  
May-09-20 01:31PM  
May-07-20 09:15AM  
Apr-30-20 12:34PM  
Apr-28-20 04:30PM  
Apr-13-20 12:00PM  
Apr-06-20 06:26PM  
Mar-31-20 07:30AM  
Mar-24-20 04:19PM  
Feb-27-20 08:55AM  
Feb-20-20 10:53AM  
Feb-19-20 12:31PM  
Feb-12-20 09:33AM  
Feb-10-20 07:30AM  
Feb-07-20 08:54AM  
Jan-17-20 02:09PM  
Jan-09-20 07:30AM  
Jan-06-20 11:00PM  
Dec-30-19 04:07PM  
Dec-25-19 11:30AM  
Dec-17-19 06:00AM  
Dec-14-19 09:13PM  
Dec-10-19 10:38AM  
Dec-05-19 03:49AM  
Dec-04-19 09:42AM  
Dec-03-19 01:03AM  
Dec-02-19 06:33AM  
Nov-26-19 08:00AM  
Nov-20-19 03:11PM  
Nov-19-19 10:46AM  
Nov-13-19 01:01AM  
Nov-07-19 09:44AM  
Oct-31-19 09:15AM  
Oct-30-19 08:34PM  
Oct-29-19 04:05PM  
Oct-24-19 08:00AM  
Oct-23-19 10:33AM  
Oct-16-19 08:00AM  
Oct-07-19 06:00AM  
Sep-30-19 08:00AM  
Sep-26-19 04:30PM  
Sep-11-19 01:18PM  
Aug-06-19 05:43AM  
Aug-01-19 12:23PM  
Jul-31-19 12:41PM  
Jul-30-19 08:00AM  
Jul-25-19 07:30AM  
Jul-10-19 08:16AM  
Jul-09-19 10:49AM  
Jul-05-19 08:57AM  
Jun-29-19 08:22PM  
Jun-14-19 09:00AM  
Jun-10-19 07:47AM  
May-30-19 04:30PM  
May-28-19 07:50AM  
May-09-19 07:20PM  
May-07-19 04:01PM  
May-06-19 06:05PM  
May-02-19 01:16PM  
Apr-29-19 07:30AM  
Apr-25-19 07:30AM  
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company develops in vivo programs focusing on liver diseases, including transthyretin amyloidosis and hereditary angioedema, as well as other research programs comprising primary hyperoxaluria Type 1, alpha-1 antitrypsin deficiency, and Hemophilia B. Its ex vivo pipeline includes proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune diseases; partnered programs focused on chimeric antigen receptor T cells and hematopoietic stem cells; and acute myeloid leukemia. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc.; Regeneron Pharmaceuticals, Inc.; and Ospedale San Raffaele. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LEONARD JOHN M.President and CEOJul 01Option Exercise6.835,00034,150472,352Jul 02 04:10 PM
LEONARD JOHN M.President and CEOJul 01Sale21.835,000109,150467,352Jul 02 04:10 PM
Rivera Jose EEVP, General CounselJun 16Option Exercise6.8310,00068,30027,897Jun 18 05:00 PM
Rivera Jose EEVP, General CounselJun 16Sale21.005,615117,91522,282Jun 18 05:00 PM
LEONARD JOHN M.President and CEOJun 03Option Exercise6.835,00034,150472,352Jun 05 05:18 PM
LEONARD JOHN M.President and CEOJun 03Sale21.835,000109,150467,352Jun 05 05:18 PM
Rivera Jose EEVP, General CounselMay 26Option Exercise6.8310,00068,300285,722May 28 05:23 PM
Rivera Jose EEVP, General CounselMay 26Sale21.215,615119,094280,107May 28 05:23 PM